我国公共卫生领域面临的突出生物安全问题

杨启凡; 王宇萍

doi:10.11847/zgggws1140136

我国公共卫生领域面临的突出生物安全问题

doi: 10.11847/zgggws1140136

杨启凡,
王宇萍^,

中国医学科学院北京协和医学院群医学及公共卫生学院，北京 100730

基金项目: 北京市教委支持国家“双一流”高校建设项目（2021 – EFT – Z – 009）

详细信息

作者简介:
杨启凡（1997 – ），女，天津人，硕士在读，研究方向：公共卫生

通讯作者:
王宇萍，E-mail：wyppumc@163.com

中图分类号: R 184
计量
- 文章访问数: 176
- HTML全文浏览量: 49
- PDF下载量: 61
- 被引次数: 0
出版历程
- 接收日期: 2022-08-24
- 网络出版日期: 2023-02-24
- 刊出日期: 2023-05-10

Research on prominent biosafety issues in the field of public health in China: a review

YANG Qifan,
WANG Yuping^,

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

摘要

摘要: 2020年10月17日，我国正式通过了《中华人民共和国生物安全法》，将生物安全列为国家安全的重要组成部分，明确了生物安全的重要地位。在新冠病毒感染疫情背景下，公共卫生领域发展广受重视。本文通过阐述生物安全与公共卫生的范畴，从新发突发传染病疫情、实验室生物安全和微生物耐药等方面，对当前我国公共卫生领域面临的生物安全风险进行综述，为促进我国公共卫生事业提供生物安全的参考视角。
- 公共卫生 /
- 生物安全 /
- 新发突发传染病 /
- 实验室生物安全 /
- 微生物耐药
Abstract: On October 17, 2020, China officially passed the Biosafety Law of the People's Republic of China, which lists biosecurity as an important part of national security and clarifies the important status of biosafety. The development of public health has received wide attention in the context of coronavirus disease 2019 (COVID - 19) pandemic. By expounding the scope of biosafety and public health, we review current biosafety risks in the field of public health in China from the aspects of emerging infectious disease outbreaks, laboratory biosafety and microbial resistance for providing a reference to relevant studies and practices.
- public health /
- biosafety /
- emerging infectious disease /
- laboratory biosafety /
- microbial resistance

HTML全文

参考文献(48)

[1]	罗亚文. 总体国家安全观视域下生物安全概念及思考[J]. 重庆社会科学, 2020(7): 63 – 72. doi: 10.19631/j.cnki.css.2020.007.005
[2]	Beeckman DSA, Rüdelsheim P. Biosafety and biosecurity in containment: a regulatory overview[J]. Frontiers in Bioengineering and Biotechnology, 2020, 8: 650. doi: 10.3389/fbioe.2020.00650
[3]	黄翠, 汤华山, 梁慧刚, 等. 全球生物安全与生物安全实验室的起源和发展[J]. 中国家禽, 2021, 43(9): 84 – 90. doi: 10.16372/j.issn.1004-6364.2021.09.015
[4]	冯显威, 陈曼莉. 现代公共卫生的概念特征及发展方向研究[J]. 医学与哲学, 2005, 26(8): 11 – 13.
[5]	蔡伟芹, 李程跃, 马安宁, 等. 基于内容分析法的公共卫生经典内涵研究[J]. 中国公共卫生, 2021, 37(11): 1667 – 1671. doi: 10.11847/zgggws1127898
[6]	蔡伟芹, 李程跃, 马安宁, 等. 基于继承与发展的公共卫生概念界定研究[J]. 中国公共卫生, 2020, 36(2): 140 – 144. doi: 10.11847/zgggws1127897
[7]	Jarvis T, Scott F, El-Jardali F, et al. Defining and classifying public health systems: a critical interpretive synthesis[J]. Health Research Policy and Systems, 2020, 18(1): 68. doi: 10.1186/s12961-020-00583-z
[8]	中华人民共和国第十三届全国人民代表大会常务委员会. 中华人民共和国生物安全法[EB/OL]. (2020 – 10 – 17)[2022 – 06 – 30]. http://www.npc.gov.cn/npc/c30834/202010/bb3bee5122854893a69acf4005a66059.shtml.
[9]	Chan-Yeung M, Xu RH. SARS: epidemiology[J]. Respirology, 2003, 8(S1): S9 – S14. doi: 10.1046/j.1440-1843.2003.00518.x
[10]	Yu H, Jing H, Chen Z, et al. Human Streptococcus suis outbreak, Sichuan, China[J]. Emerging Infectious Diseases, 2006, 12(6): 914 – 920. doi: 10.3201/eid1206.051194
[11]	Xu CL, Dong LB, Xin L, et al. Human avian influenza A (H5N1) virus infection in China[J]. Science in China Series C:Life Sciences, 2009, 52(5): 407 – 411. doi: 10.1007/s11427-009-0067-7
[12]	Zhou L, Liao QH, Dong LB, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China[J]. The Journal of Infectious Diseases, 2009, 199(12): 1726 – 1734. doi: 10.1086/599206
[13]	陶律延, 梁张, 宝福凯, 等. 中国人粒细胞无形体病的研究进展[J]. 中国热带医学, 2017, 17(2): 193 – 197. doi: 10.13604/j.cnki.46-1064/r.2017.02.23
[14]	Li HY, Zhou Y, Wang WJ, et al. The clinical characteristics and outcomes of patients with human granulocytic anaplasmosis in China[J]. International Journal of Infectious Diseases, 2011, 15(12): e859 – e866. doi: 10.1016/j.ijid.2011.09.008
[15]	Yang F, Ren LL, Xiong ZH, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008[J]. Journal of Clinical Microbiology, 2009, 47(7): 2351 – 2352. doi: 10.1128/JCM.00563-09
[16]	Yu XJ, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China[J]. New England Journal of Medicine, 2011, 364(16): 1523 – 1532. doi: 10.1056/NEJMoa1010095
[17]	Xu B, Tian HY, Sabel CE, et al. Impacts of road traffic network and socioeconomic factors on the diffusion of 2009 pandemic influenza A (H1N1) in Mainland China[J]. International Journal of Environmental Research and Public Health, 2019, 16(7): 1223. doi: 10.3390/ijerph16071223
[18]	李群. 我国新发传染病应对形势和任务[J]. 中华疾病控制杂志, 2020, 24(2): 125 – 127, 244. doi: 10.16462/j.cnki.zhjbkz.2020.02.001
[19]	李婉宜, 李华, 邝玉, 等. 病原生物实验室生物安全保障体系的建设与思考[J]. 实验科学与技术, 2013, 11(1): 155 – 157. doi: 10.3969/j.issn.1672-4550.2013.01.053
[20]	Peng HS, Bilal M, Iqbal HMN. Improved biosafety and biosecurity measures and/or strategies to tackle laboratory - acquired infections and related risks[J]. International Journal of Environmental Research and Public Health, 2018, 15(12): 2697. doi: 10.3390/ijerph15122697
[21]	Wu GZ. Laboratory biosafety in China: past, present, and future[J]. Biosafety and Health, 2019, 1(2): 56 – 58. doi: 10.1016/j.bsheal.2019.10.003
[22]	Yuan ZM. Current status and future challenges of high - level biosafety laboratories in China[J]. Journal of Biosafety and Biosecurity, 2019, 1(2): 123 – 127. doi: 10.1016/j.jobb.2019.09.005
[23]	刘琦, 卢耀勤, 刘涛. 国内外生物安全实验室的研究进展[J]. 职业与健康, 2021, 37(12): 1724 – 1728. doi: 10.13329/j.cnki.zyyjk.2021.0426
[24]	Liu SY, Bi YJ, Liu YW. Modeling and dynamic analysis of tuberculosis in mainland China from 1998 to 2017: the effect of DOTS strategy and further control[J]. Journal of Biosafety and Biosecurity, 2020, 17(1): 6.
[25]	王黎霞, 成诗明, 陈明亭, 等. 2010年全国第五次结核病流行病学抽样调查报告[J]. 中国防痨杂志, 2012, 34(8): 485 – 508.
[26]	Pang Y, Lu J, Huo FM, et al. Prevalence and treatment outcome of extensively drug - resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: a five-year review[J]. Journal of Infection, 2017, 75(5): 433 – 440. doi: 10.1016/j.jinf.2017.08.005
[27]	Zhao YL, Xu SF, Wang LX, et al. National survey of drug - resistant tuberculosis in China[J]. New England Journal of Medicine, 2012, 366(23): 2161 – 2170. doi: 10.1056/NEJMoa1108789
[28]	Liao S, Cai C, Huo FM, et al. Trends in drug - resistant tuberculosis in China: data from a clinical tuberculosis centre[J]. International Union Against Tuberculosis and Lung Disease, 2017, 21(9): 990 – 995. doi: 10.5588/ijtld.17.0086
[29]	Jiao WW, Liu ZG, Han R, et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China[J]. Tuberculosis, 2015, 95(3): 315 – 320. doi: 10.1016/j.tube.2015.02.041
[30]	Ding PP, Li XW, Jia ZW, et al. Multidrug - resistant tuberculosis (MDR - TB) disease burden in China: a systematic review and spatio - temporal analysis[J]. BMC Infectious Diseases, 2017, 17(1): 57. doi: 10.1186/s12879-016-2151-5
[31]	Zhang JY, Gou HM, Hu XJ, et al. Status of drug - resistant tuberculosis in China: a systematic review and meta-analysis[J]. American Journal of Infection Control, 2016, 44(6): 671 – 676. doi: 10.1016/j.ajic.2015.12.042
[32]	Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005 – 2014[J]. Clinical Microbiology and Infection, 2016, 22(S1): S9 – S14.
[33]	Hu FP, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018[J]. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38(12): 2275 – 2281. doi: 10.1007/s10096-019-03673-1
[34]	胡付品, 郭燕, 朱德妹, 等. 2019年CHINET三级医院细菌耐药监测[J]. 中国感染与化疗杂志, 2020, 20(3): 233 – 243. doi: 10.16718/j.1009-7708.2020.03.001
[35]	胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(4): 377 – 387. doi: 10.16718/j.1009-7708.2021.04.001
[36]	Peng XS, Zhu QX, Liu J, et al. Prevalence and antimicrobial resistance patterns of bacteria isolated from cerebrospinal fluid among children with bacterial meningitis in China from 2016 to 2018: a multicenter retrospective study[J]. Antimicrobial Resi-stance and Infection Control, 2021, 10(1): 24. doi: 10.1186/s13756-021-00895-x
[37]	Fu P, Xu HM, Jing CM, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED Program in China, 2016 to 2020[J]. Microbiology Spectrum, 2021, 9(3): e0028321. doi: 10.1128/Spectrum.00283-21
[38]	Xiao M, Sun ZY, Kang M, et al. Five - year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF - NET) study[J]. Journal of Clinical Microbiology, 2018, 56(7): e00577.
[39]	Xiao M, Chen SCA, Kong FR, et al. Distribution and antifungal susceptibility of Candida species causing candidemia in China: an update from the CHIF - NET study[J]. The Journal of Infectious Diseases, 2020, 221(S2): S139 – S147.
[40]	Wang Y, Fan X, Wang H, et al. Continual decline in azole susceptibility rates in Candida tropicalis over a 9 - year period in China[J]. Frontiers in Microbiology, 2021, 12: 702839.
[41]	Xiao M, Chen SCA, Kong FR, et al. Five - year China Hospital Invasive Fungal Surveillance Net (CHIF - NET) study of invasive fungal infections caused by noncandidal yeasts: species distribution and azole susceptibility[J]. Infection and Drug Resistance, 2018, 11: 1659 – 1667. doi: 10.2147/IDR.S173805
[42]	井然, 侯欣, 肖盟, 等. 中国侵袭性真菌耐药监测网成员单位重症监护室侵袭性酵母的分布特征及其对唑类药物敏感性的变迁[J]. 中国感染与化疗杂志, 2020, 20(2): 175 – 180. doi: 10.16718/j.1009-7708.2020.02.012
[43]	Zhang Q, Liao Y, Chen J, et al. Epidemiology study of HBV genotypes and antiviral drug resistance in multi - ethnic regions from western China[J]. Scientific Reports, 2015, 5: 17413. doi: 10.1038/srep17413
[44]	Guo XH, Wu JS, Wei FL, et al. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009 – 2016: a retrospective study[J]. International Journal of Antimicrobial Agents, 2018, 52(2): 201 – 209. doi: 10.1016/j.ijantimicag.2018.04.002
[45]	Zuo ZB, Liang S, Sun XG, et al. Drug resistance and virological failure among HIV - infected patients after a decade of antiretroviral treatment expansion in eight provinces of China[J]. PLoS One, 2016, 11(12): e0166661. doi: 10.1371/journal.pone.0166661
[46]	Yuan D, Du ZL, Zhou JM, et al. HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017[J]. Medicine, 2019, 98(43): e17585. doi: 10.1097/MD.0000000000017585
[47]	Ye JR, Hao MQ, Xing H, et al. Transmitted HIV drug resistance among individuals with newly diagnosed HIV infection: a multicenter observational study[J]. Aids, 2020, 34(4): 609 – 619. doi: 10.1097/QAD.0000000000002468
[48]	Jia HH, Li KW, Chen QY, et al. High prevalence of HBV lamivudine - resistant mutations in HBV/HIV co - infected patients on antiretroviral therapy in the area with the highest prevalence of HIV/HBV co - infection in China[J]. Intervirology, 2018, 61(3): 123 – 132. doi: 10.1159/000493797